國家衛生研究院 NHRI:Item 3990099045/11014
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 909623      Online Users : 821
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11014


    Title: Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer
    Authors: Hsieh, HP;Hsu, JTA;Yeh, TK;Chen, CT
    Contributors: Institute of Biotechnology and Pharmaceutical Research
    Abstract: Lung cancer is one of the chief causes of cancer death in the world; in addition, non-small cell lung cancer (NSCLC) accounts for 85% of the lung cancer deaths. The development of tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have shown remarkable effects in patients but some acquired resistance after treatment. Therefore, the discovery of efficacious EGFR-TKIs poses an utmost priority. Our team at IBPR has designed and synthesized a series of compounds by high throughput parallel synthesis platform and then identified DBPR112 as a potent EGFR-TKI clinical candidate, showing IC50 of 2 nM in HCC827 cells, and excellent inhibitory ability on EGFRWT and EGFRDM. DBPR112 was orally effective against the growth of human lung HCC827 tumors subcutaneously xenografted in nude mice. A dramatic reduction in tumor size was noted with DBPR112 treatment, while displaying negligible body weight loss in all dosing groups. Futhermore, DBPR112 was more tolerable than afatinib in mice. To date, all pre-clinical studies were completed, the IND application of DBPR112 was approved by US FDA and the Phase I clinical trial protocol was also approved by Taiwan FDA.
    Date: 2018-01
    Relation: Cancer Science. 2018 Jan;109(Suppl. 1):739.
    Link to: http://dx.doi.org/10.1111/cas.13499
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1347-9032&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000422694004333
    Appears in Collections:[Chiung-Tong Chen] Conference Papers/Meeting Abstract
    [Teng-Kuang Yeh] Conference Papers/Meeting Abstract
    [John Tsu-An Hsu] Conference Papers/Meeting Abstract
    [Hsing-Pang Hsieh] Conference Papers/Meeting Abstract

    Files in This Item:

    File SizeFormat
    ISI000422694004333.pdf48KbAdobe PDF327View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback